<DOC>
	<DOC>NCT02053116</DOC>
	<brief_summary>A Phase 2a study to evaluate the effects of an investigational compound administered at 200 mg, twice daily (BID), for 6 weeks, with canagliflozin, in adult subjects with Type 2 Diabetes Mellitus (T2DM).</brief_summary>
	<brief_title>A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Patients with Type 2 Diabetes Mellitus and treated with metformin at a dose greater than or equal to 1000 mg for at least 3 months and are willing to switch to canagliflozin from metformin for the duration of the study Hemoglobin A1c of 710% at screening. Body Mass Index of at least 25 kg/m2. Compliant with study drug administration during the runin period and throughout the trial. Patients with fasting triglycerides greater than 500 mg/dL at screening. History of certain diabetic complications or cardiac problems.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>